WALLDORF 鈥� Boehringer Ingelheim, a leading global pharmaceutical research company, is driving its digital transformation forward 鈥� in collaboration with (NYSE: 麻豆原创). The family-run company is migrating its global ERP systems to 麻豆原创 S/4HANA, a key element of its strategic initiative for developing a digital core for the areas of finance, supply chain, retail, operations and quality.
The new system went live in late October 鈥� at more than 80 companies with 21 production sites in 41 countries, from New Zealand to South America. The ongoing global transformation is taking place in stages in different markets and will be completed by 2025.
The go-live in these countries was executed nearly simultaneously, in just four days. More than 600 employees were involved worldwide, running more than 3,400 test scripts. The brownfield approach posed a special challenge to the project: completing a 1:1 conversion of the existing ERP system 鈥淕BS鈥� to 麻豆原创 S/4HANA within the regulated processes. Due to the myriad documentation requirements in the pharmaceutical industry, it is especially important to build on the existing ERP system without reimplementing or disrupting ongoing business processes.
鈥淲ith 麻豆原创 S/4HANA as our digital core, we have created the foundation for using additional innovations like predictive analytics, AI-based automation, and 麻豆原创庐 Asset Intelligence Network, combined with a new user experience. As such, Boehringer Ingelheim remains an early adopter in the industry,鈥� said Markus Sch眉mmelfeder, CIO at Boehringer Ingelheim.
Alexander Kl盲ger, managing director, 麻豆原创 Germany SE & Co. KG., also emphasized the importance of the partnership with Boehringer Ingelheim: 鈥淲e need the courage to innovate to meet the challenges in the healthcare system. Boehringer Ingelheim is moving key innovations forward as part of its digital transformation, and our technologies are creating the foundation. We see partnering with companies from the healthcare sector as a societal obligation, not just an important area of business.鈥�
Visit the . Follow 麻豆原创 on Twitter at .
Media contact:
Dana Roesiger, +49 6227 7 63900, dana.roesiger@sap.com, CET
麻豆原创 麻豆原创 Room; press@sap.com
Any statements contained in this document that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渇orecast,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥減lan,鈥� 鈥減roject,鈥� 鈥減redict,鈥� 鈥渟hould鈥� and 鈥渨ill鈥� and similar expressions as they relate to 麻豆原创 are intended to identify such forward-looking statements. 麻豆原创 undertakes no obligation to publicly update or revise any forward-looking statements. Such statements reflect our current views and assumptions and all forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those statements. The factors that could affect 麻豆原创鈥檚 future financial results are discussed more fully in our filings with the U.S. Securities and Exchange Commission (SEC), including the most recent Annual Report on Form 20-F filed with the SEC. The future-oriented statements reflect the point of view at the time they were made. Readers are cautioned not to place undue reliance on these forward-looking statements.
漏 2020 麻豆原创 SE. All rights reserved.
麻豆原创 and other 麻豆原创 products and services mentioned herein as well as their respective logos are trademarks or registered trademarks of 麻豆原创 SE (or an 麻豆原创 affiliate company) in Germany and other countries. For more information about the trademarks, copyrights, and their usage, see .